Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.53 |
| ▸ | RAB9A | P51151 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.41 |
| ▸ | CBFB | Q13951 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775052 | 1.00 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL1896253 | 0.98 | PDK1 (0.56) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL30190003 | 0.77 | PDK1 (0.60) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL140126 | 0.77 | PDK1 (0.60) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL137507 | 0.75 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL13310867 | 0.75 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2642887 | 0.75 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL15689525 | 0.75 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL1761326 | 0.75 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL2176039 | 0.75 | PDK1 (0.58) | PDK1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20050112770-A1 | Method for optical measurement of multi-stranded nucleic acid | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| EP-1362894-A2 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJI PHOTO FILM CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-5616717-A | Process for the preparation of pure enantiomers of 1-(2-pyridyl)-2-cyclohexylethylamine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5552421-A | Leukotriene biosynthesis inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5374644-A | Insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-20 | — | — | US | disclosed |
| US-5296486-A | Leukotriene biosynthesis inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0535521-A2 | Condensed oxazole and thiazole derivatives as leukotriene biosynthesis inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| EP-0256667-B1 | SUBSTITUTED PHENYL-2-PROPENOIC ACID DERIVATIVES USEFUL IN AGRICULTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-12-30 | — | — | EP | disclosed |
| EP-0256667-A2 | Substituted phenyl-2-propenoic acid derivatives useful in agriculture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, PGC | PDK1 291/4885NPC1 466/4885RAB9A 2219/4885 |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PDK1 3666/4885NPC1 100/4885RAB9A 1724/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | PDK1 1837/4885NPC1 4285/4885RAB9A 1966/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | PDK1 1614/4885NPC1 492/4885RAB9A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.